Novartis lacks confidence in AI says CEO
WASHINGTON: Technology was reshaping healthcare, from pharmaceutical research to detecting opioid addiction, but the magnitude and pace of change wasn’t always as dramatic as some had hoped a few years ago, industry leaders said at The Wall Street Journal Health Forum on Tuesday.
Novartis chief executive Vas Narasimhan said that for now, the opportunities presented by artificial intelligence were on the margin. “It’s another tool in the toolbox,” he said.
Doctors, insurers and drugmakers are experimenting with digital technology at a brisk pace after years of watching from the sidelines as ubiquitous internet access and smartphones disrupted nearly every other sector of the economy. They hope automation and data-driven predictions can create new efficiencies in an industry that contributes nearly 18 per cent of US gross domestic product.
Pharmaceutical companies hope artificial intelligence algorithms can help scientists discover new drugs and improve the industry’s poor success rate in bringing treatments from clinical trials to regulatory approval.
Novartis has invested heavily in AI programs in hopes of squeezing more products out of its nearly $US9 billion ($12.8bn) annual research-and-development budget. So far, though, the Swiss drug-maker has had the most success using artificial intelligence to forecast its financial results and clinical-trial enrolment, Dr Narasimhan told the forum in Washington.
Dr Narasimhan said he was more sceptical that AI could keep up with the rapid advances in complex diseases like cancer, or predict which drugs would work better than humans can.
Pfizer executive chairman Ian
C. Read agreed, saying in a later session that AI’s capabilities were restricted by gaps in human knowledge about how diseases functioned in the body.
“Using AI in drug discovery is extremely difficult and unlikely to be productive in the near term because our understanding of biology is not as deep as we’d like to believe it to be,” Mr Read said.
Still, even applying digital record-keeping and communication could add up to significant financial savings, both men said. Dr Narasimhan said studies showed drug companies could cut about 20 per cent from research-and-development costs by using certain technologies at a broad scale.
Mr Read said a big contributor to high development costs was an antiquated system of running clinical trials that still relied on paper records and in-person visits with trial sites. “It’s just a nightmare,“ he said.






